RE:RE:Gilead sees 33% revenues will come from oncology by 2030 In the last few years Big Pharma companies have been busy selling off noncore assets in areas such as consumer health, animal health, generics or smaller brands.
Through the spinoffs, the companies have become more focused in just a few areas of interest such as high-value immunology and oncology assets.
The spinoff of non-core assets is just a natural progression of Big Pharma's life cycle which is to now diversify its existing pipeline (adjacencies) and expand into different therapeutic areas, such as inflammatory diseases and cancer, to continue their growth story.
With the right effort, ONCY appears positioned to capitalize on Big Pharma's new focus and areas of therapeutic diversification.